NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/21/2025
Back to search
Official data from USPTO
DIVITUM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
DIVITUM
ST13
US500000079344278Class
1, 5, 42, 44
Filing
79344278
Registration
7129071
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
44
Latest update
11/23/2025
Trademark type
Word
Nice classes
1, 5, 42, 44
Filing date
04/13/2022
Registration date
08/08/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
08/08/2023
Last transaction
11/23/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
64
Owner location
SE
Examiner
LOZEAU,BRANDON THOMAS
Law office
N90
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Biovica International AB
Representatives
Mark H. Tidman Baker & Hostetler LLP
Technical classification
Nice Classes
Class 1Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Diagnostic preparations for scientific or research use; diagnostic agents and reagents for scientific or research use
Class 5
Diagnostic agents and reagentspreparations and substances for medical and veterinary purposes for the measurement of cell division; diagnostic agents and reagentspreparations and substances for measuring enzyme activity for medical and veterinary purposes; diagnostic kits comprised of medical diagnostic reagents and biomarker assays to monitor and predict treatment response in cancer therapy; diagnostic kits comprised of medical diagnostic reagents and biomarker assays to monitor and predict treatment response in viral diseases; diagnostic kits comprised of medical diagnostic reagents and biomarker assays to monitor and predict treatment response in autoimmune diseases
Class 42
Scientific laboratory services and scientific research and analysis regarding monitoring and predicting treatment response to cancer therapyin viral therapy and autoimmune therapy; scientific laboratory services and research and analysis regarding measuring the activity of enzyme in blood serum or cell cultures; research and development in the field of diagnostic preparations; scientific research and developmentdiagnostic development; data science servicescompiling data for research purposes in the field of biostatistics; laboratory biomarker analysis services and related data analysis; biochemical analysis; medical laboratory services; conducting preclinical studies in the nature of scientific feasibility studies; medical laboratory services regarding measurement of cell division; conducting scientific feasibility studiespreclinical studies regarding measurement of cell proliferation; medical laboratory services regarding measurement of enzymatic activity; conducting scientific feasibility studiespreclinical studies regarding measurement of enzymatic activity
Class 44
Medicalbiomedical and veterinary diagnostic monitoring and testing services regarding blood serum or plasma samples or cell cultures; medicalbiomedical and veterinary diagnostic monitoring and testing services regarding measurement of cell proliferation; medicalbiomedical and veterinary diagnostic monitoring and testing services regarding measurement of enzymatic activity; provision of medical information and advice relating to the use of medical and veterinary diagnostic equipment; medical testing for diagnostic or treatment purposesconducting tests to identify diseases affecting cell divisioncancerviral and autoimmune diseases; medical analysis regarding the identification and monitoring of cancervirus and autoimmune diseases and other diseases that cause cell growth for the diagnosis and treatment of persons
Publications
History of USPTO decisions and trademark events.
44 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/03/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
11/13/2023
FIMP
FINAL DISPOSITION PROCESSED
11/13/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
11/08/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
08/08/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
08/08/2023
GPNX
NOTIFICATION PROCESSED BY IB
05/24/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/23/2023
PUBO
PUBLISHED FOR OPPOSITION
05/23/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/03/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
05/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
05/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/20/2023
RFNT
REFUSAL PROCESSED BY IB
04/20/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
04/14/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/13/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/13/2023
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/06/2023
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
04/06/2023
EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
04/06/2023
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/06/2023
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/06/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/29/2023
RFRR
REFUSAL PROCESSED BY MPU
03/29/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/03/2023
CNRT
NON-FINAL ACTION WRITTEN
02/02/2023
DOCK
ASSIGNED TO EXAMINER
01/31/2023
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/24/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/24/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/24/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/24/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/24/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/24/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/10/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
10/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
10/10/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/18/2022
MAFR
APPLICATION FILING RECEIPT MAILED
07/12/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/08/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
07/07/2022
Continuous trademark protection
Get notified about every new filing that threatens DIVITUM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.